Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NTRA 
Natera Inc (NTRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NTRA (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 92.63% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.46B USD | Price to earnings Ratio - | 1Y Target Price 189.62 |
Price to earnings Ratio - | 1Y Target Price 189.62 | ||
Volume (30-day avg) 2119864 | Beta 1.8 | 52 Weeks Range 83.13 - 183.00 | Updated Date 04/1/2025 |
52 Weeks Range 83.13 - 183.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.22% | Operating Margin (TTM) -13.6% |
Management Effectiveness
Return on Assets (TTM) -8.96% | Return on Equity (TTM) -19.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18335520279 | Price to Sales(TTM) 11.47 |
Enterprise Value 18335520279 | Price to Sales(TTM) 11.47 | ||
Enterprise Value to Revenue 10.81 | Enterprise Value to EBITDA -26.8 | Shares Outstanding 135186000 | Shares Floating 130688540 |
Shares Outstanding 135186000 | Shares Floating 130688540 | ||
Percent Insiders 3.45 | Percent Institutions 93.64 |
Analyst Ratings
Rating 4.56 | Target Price 171.93 | Buy 5 | Strong Buy 12 |
Buy 5 | Strong Buy 12 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Natera Inc
Company Overview
History and Background
Natera, Inc. was founded in 2003. It is a genetic testing company that focuses on non-invasive methods for prenatal and cancer screening, aiming to improve reproductive health and cancer diagnostics through its proprietary technology. Initially focused on non-invasive prenatal testing (NIPT), Natera has expanded its offerings to include cancer screening and monitoring tests.
Core Business Areas
- Reproductive Health: Offers a suite of genetic tests, including Panorama for NIPT, Vistara for single-gene mutations, and Horizon for carrier screening. These tests analyze fetal DNA from a maternal blood sample to assess the risk of genetic conditions.
- Oncology: Provides Signatera, a personalized ctDNA test used for cancer recurrence monitoring, treatment response assessment, and minimal residual disease (MRD) detection.
Leadership and Structure
The CEO of Natera is Steve Chapman. The company has a board of directors and a management team overseeing its operations. The organizational structure is divided by functional areas such as R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Panorama NIPT: A non-invasive prenatal test that screens for common chromosomal abnormalities in a fetus, such as Down syndrome. Competitors include Illumina (VERIseq) and Roche (Harmony). Market share is significant but fluctuates with pricing and reimbursement changes. Revenue attributed to this product is a substantial portion of their Reproductive Health segment.
- Signatera: A personalized ctDNA test for cancer patients that monitors for minimal residual disease (MRD) and recurrence. Competitors include Guardant Health (Guardant360) and Exact Sciences (OncoExome). Signatera is growing rapidly, and revenue attributed to oncology is increasing.
Market Dynamics
Industry Overview
The genetic testing market is rapidly growing, driven by advancements in technology, increasing awareness, and demand for personalized medicine. Key trends include the expansion of NIPT, the development of liquid biopsy technologies for cancer, and the rise of direct-to-consumer genetic testing.
Positioning
Natera is a key player in the NIPT and ctDNA testing markets. Its competitive advantages include its proprietary technology, established relationships with healthcare providers, and a strong brand reputation.
Total Addressable Market (TAM)
The estimated TAM for NIPT and cancer liquid biopsy is significant. The global NIPT market is projected to reach billions of dollars by 2030, and the liquid biopsy market is even larger. Natera is positioned to capture a substantial share of this growing market through innovation and expansion of its product portfolio.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Strong brand recognition in NIPT
- Growing presence in oncology testing
- Established relationships with healthcare providers
- Extensive patent portfolio
Weaknesses
- High operating expenses
- Dependence on reimbursement policies
- Competition from larger players
- Negative press regarding billing practices
- Ongoing legal disputes
Opportunities
- Expansion into new geographic markets
- Development of new genetic tests
- Partnerships with pharmaceutical companies
- Increased adoption of liquid biopsy for cancer
- Advancements in AI-driven data analysis
Threats
- Changes in reimbursement policies
- Increased competition
- Technological disruptions
- Regulatory challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- ILMN
- ROCHE
- EXAS
- GH
Competitive Landscape
Natera competes with larger companies with established market presence and extensive resources. Natera has to be innovative and more focused to compete in this market. The competition is intense and relies on accuracy and competitive pricing.
Major Acquisitions
Genetic Prediction
- Year: 2021
- Acquisition Price (USD millions): 73
- Strategic Rationale: Acquired to integrate polygenic risk scoring into Natera's reproductive health portfolio.
Growth Trajectory and Initiatives
Historical Growth: Natera has experienced significant revenue growth over the past several years, driven by increased adoption of its NIPT and ctDNA testing products.
Future Projections: Analysts project continued revenue growth for Natera, driven by expansion in the oncology market and increased adoption of NIPT globally. Profitability is expected to improve as the company scales its operations.
Recent Initiatives: Recent initiatives include expanding the Signatera test for new cancer types, launching new partnerships with pharmaceutical companies, and investing in AI-driven data analysis.
Summary
Natera shows promise with consistent revenue growth, particularly in oncology, but faces profitability challenges due to high operating expenses. The company has a competitive advantage in its proprietary technology. Key things to watch out for is competition and reimbursement policies. Natera may need to find additional funding with the negative cash flow.
Similar Companies
EXAS
EXACT Sciences Corporation
EXAS
EXACT Sciences Corporation
GH
Guardant Health Inc
GH
Guardant Health Inc
ILMN
Illumina Inc
ILMN
Illumina Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Future projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Natera Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-07-02 | CEO & Director Mr. Steven Leonard Chapman | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 4424 | Website https://www.natera.com |
Full time employees 4424 | Website https://www.natera.com | ||
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.